Literature DB >> 14609837

Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years' experience.

Y M Bartlema1, J A Oosterhuis, J G Journée-De Korver, R E Tjho-Heslinga, J E E Keunen.   

Abstract

AIM: To evaluate the results of combined plaque radiotherapy and transpupillary thermotherapy (TTT) in 50 consecutive patients 5 years after treatment.
METHODS: 50 adult patients with choroidal melanoma were treated with ruthenium-106 ((106)Ru) plaque radiotherapy combined with TTT. A flat scar was the preferred end point of treatment. The mean tumour thickness was 3.9 mm (range 1.5-8.0 mm), the mean tumour diameter was 11.3 mm (range 5.8-15.0 mm). TTT was performed with an infrared diode laser at 810 nm, a beam diameter of 2-3 mm, and 1 minute exposures. Tumours >5 mm thick received an episcleral contact dose of 800 Gy (106)Ru; tumours <or=5 mm thick received a contact dose of 600 Gy (106)Ru. TTT was repeated in case of incomplete tumour regression after combined therapy.
RESULTS: Complete tumour regression was obtained in 45 patients. It required one, two, or three TTT sessions in 32, 11, and two patients, respectively. In tumours <or=3 mm thick complete flattening was achieved significantly faster than in tumours >3 mm thick (log rank test p = 0.01). Eight melanomas were amelanotic, seven of which required multiple TTT sessions. In one patient the tumour recurred at the central margin of the treated area; this eye was enucleated. In one patient the tumour failed to regress 6 months after treatment and enucleation was performed at the patient's request. Three eyes developed severe proliferative retinopathy. Radiation maculopathy caused a loss of the best corrected visual acuity: before treatment 31 patients had a best corrected visual acuity of 20/60 or better but in only 12 patients did it remain in this range 5 years after treatment. Three patients developed distant metastasis to the liver.
CONCLUSION: The 5 year results for combined plaque radiotherapy and TTT as treatment for choroidal melanoma are favourable in terms of complete tumour regression and low rate of recurrences; however, there was considerable loss of visual acuity as a result of radiation maculopathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14609837      PMCID: PMC1771877          DOI: 10.1136/bjo.87.11.1370

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  23 in total

1.  Transpupillary thermotherapy of choroidal melanoma with or without brachytherapy: a dilemma.

Authors:  J E Keunen; J G Journée-de Korver; J A Oosterhuis
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Intrascleral recurrence of uveal melanoma after transretinal "endoresection".

Authors:  B Damato; D Wong; F D Green; J M Mackenzie
Journal:  Br J Ophthalmol       Date:  2001-01       Impact factor: 4.638

3.  Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations.

Authors:  Carol L Shields; Jerry A Shields; Noel Perez; Arun D Singh; Jacqueline Cater
Journal:  Ophthalmology       Date:  2002-02       Impact factor: 12.079

4.  Transscleral laser thermotherapy of hamster Greene melanoma: inducing tumour necrosis without scleral damage.

Authors:  A I Rem; J A Oosterhuis; J G Korver; T J van den Berg
Journal:  Melanoma Res       Date:  2001-10       Impact factor: 3.599

5.  Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma.

Authors:  M W Wilson; J L Hungerford
Journal:  Ophthalmology       Date:  1999-08       Impact factor: 12.079

6.  Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study.

Authors:  J Pe'er; F H Stefani; S Seregard; T Kivela; P Lommatzsch; J U Prause; B Sobottka; B Damato; I Chowers
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

7.  Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients.

Authors:  C L Shields; J A Shields; J Cater; K Gündüz; C Miyamoto; B Micaily; L W Brady
Journal:  Arch Ophthalmol       Date:  2000-09

8.  Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy.

Authors:  P T Finger
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

9.  Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma.

Authors:  P K Lommatzsch; C Werschnik; E Schuster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2000-02       Impact factor: 3.117

10.  Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients.

Authors:  Carol L Shields; Jacqueline Cater; Jerry A Shields; Aning Chao; Hatem Krema; Miguel Materin; Luther W Brady
Journal:  Arch Ophthalmol       Date:  2002-07
View more
  10 in total

Review 1.  Lasers for the treatment of intraocular tumors.

Authors:  Samuel K Houston; Charles C Wykoff; Audina M Berrocal; Ditte J Hess; Timothy G Murray
Journal:  Lasers Med Sci       Date:  2013-05       Impact factor: 3.161

2.  Management of diffuse choroidal hemangioma in Sturge-Weber syndrome with Ruthenium-106 plaque radiotherapy.

Authors:  Agnieszka Kubicka-Trząska; Izabella Karska-Basta; Piotr Oleksy; Bożena Romanowska-Dixon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-26       Impact factor: 3.117

3.  Combined brachytherapy and transpupillary thermotherapy for large choroidal melanoma: tumor regression and early complications.

Authors:  Klaus-Martin Kreusel; Nikolaos Bechrakis; Juliane Riese; Lothar Krause; Joachim Wachtlin; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

4.  Ruthenium-106 plaque radiotherapy alone or in combination with transpupillary thermotherapy in the management of choroidal melanoma.

Authors:  Kaan Gündüz; Rengin Aslihan Kurt; Hale Elif Akmeşe; Kenan Köse; Omür Uçakhan-Gündüz
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

5.  [Transpupillary thermotherapy (TTT) for uveal melanomas. Long term results of a single TTT with an adapter for a conventional infrared laser].

Authors:  G Langmann; H Lechner; E Wenzel; G Mossböck; W Wackernagel
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

Review 6.  Uveal Melanoma: Current Trends in Diagnosis and Management.

Authors:  Berçin Tarlan; Hayyam Kıratlı
Journal:  Turk J Ophthalmol       Date:  2016-06-06

7.  Regression patterns of choroidal melanoma: After palladium-103 (103Pd) plaque brachytherapy.

Authors:  Abhilasha Maheshwari; Paul T Finger
Journal:  Eur J Ophthalmol       Date:  2018-05-22       Impact factor: 2.597

8.  Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment.

Authors:  Samuel K Houston; Nisha V Shah; Christina Decatur; Marcela Lonngi; William Feuer; Arnold M Markoe; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2013-01-22

9.  Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth.

Authors:  Mariam El Filali; Irene Homminga; Willem Maat; Pieter A van der Velden; Martine J Jager
Journal:  Mol Vis       Date:  2008-09-24       Impact factor: 2.367

10.  Patterns of care and survival outcomes after treatment for uveal melanoma in the post-coms era (2004-2013): a surveillance, epidemiology, and end results analysis.

Authors:  Yuan James Rao; Julia Sein; Shahed Badiyan; Julie K Schwarz; Todd DeWees; Perry Grigsby; Prabakar Kumar Rao
Journal:  J Contemp Brachytherapy       Date:  2017-10-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.